Showing all 9 results

  • memorit 10

    MEMORIT 10 – Donepezil

    This medicine increases the concentration
    of the acetylcholine neurotransmitter and is
    intended to treat mild to moderate Alzheimer’s
    disease-associated dementia.


    MEMORIT 10 – Donepezil

    This medicine increases the concentration of the acetylcholine neurotransmitter and is intended to treat mild to moderate Alzheimer’s disease-associated dementia.

    Read More

  • memorit 5

    MEMORIT 5 – Donepezil

    This medicine increases the concentration
    of the acetylcholine neurotransmitter and is
    intended to treat mild to moderate Alzheimer’s
    disease-associated dementia.


    MEMORIT 5 – Donepezil

    This medicine increases the concentration of the acetylcholine neurotransmitter and is intended to treat mild to moderate Alzheimer’s disease-associated dementia.

    Read More

  • memox-10-eng

    MEMOX 10 – Memantine

    Memox is indicated for the treatment of moderate to severe Alzheimer’s
    disease.
    Memox belongs to a class of drugs that are used to treat dementia.
    Memory loss that is typical of Alzheimer’s disease is caused by a
    disruption in transmission of neural signals in the brain.
    In the brain there is a type of receptors, called NMDA receptors. These
    receptors are involved in transmitting neural signals that are important to
    learning and memory. By acting on NMDA receptors, Memox improves
    neural signal transmission and memory.


    MEMOX 10 – Memantine

    Memox is indicated for the treatment of moderate to severe Alzheimer’s disease. Memox belongs to a class of drugs that are used to treat dementia. Memory loss that is typical of Alzheimer’s disease is caused by a disruption in transmission of neural signals in the brain. In the brain there is a type of receptors, called NMDA receptors. These receptors are involved in transmitting neural signals that are important to learning and memory. By acting on NMDA receptors, Memox improves neural signal transmission and memory.

    Read More

  • memox-20-eng

    MEMOX 20 – Memantine

    Memox is indicated for the treatment of moderate to severe Alzheimer’s
    disease.
    Memox belongs to a class of drugs that are used to treat dementia.
    Memory loss that is typical of Alzheimer’s disease is caused by a
    disruption in transmission of neural signals in the brain.
    In the brain there is a type of receptors, called NMDA receptors. These
    receptors are involved in transmitting neural signals that are important to
    learning and memory. By acting on NMDA receptors, Memox improves
    neural signal transmission and memory.


    MEMOX 20 – Memantine

    Memox is indicated for the treatment of moderate to severe Alzheimer’s disease. Memox belongs to a class of drugs that are used to treat dementia. Memory loss that is typical of Alzheimer’s disease is caused by a disruption in transmission of neural signals in the brain. In the brain there is a type of receptors, called NMDA receptors. These receptors are involved in transmitting neural signals that are important to learning and memory. By acting on NMDA receptors, Memox improves neural signal transmission and memory.

    Read More

  • rispond 1

    RISPOND 1 – Risperidone

    For the treatment of schizophrenia and symptoms
    of psychotic disorders.
    – For long-term treatment in order to sustain the
    improvement in the state of the illness in patients
    who have exhibited an initial response.
    – For the treatment of psychotic manifestations of
    moderate to severe dementia, only in Alzheimer’s
    disease (short-term treatment up to 6 weeks in
    a situation of consistent aggression), in patients
    who are not responding to non-pharmacological
    treatment and there is concern that they will harm
    themselves or others.
    – For treatment of mania in bipolar disorder.
    – For the treatment of behavioral disorders such
    as violence, impulsiveness and self aggression in
    children over 5 years of age and in adults who are
    intellectually handicapped.


    RISPOND 1 – Risperidone

    For the treatment of schizophrenia and symptoms of psychotic disorders. – For long-term treatment in order to sustain the improvement in the state of the illness in patients who have exhibited an initial response. – For the treatment of psychotic manifestations of moderate to severe dementia, only in Alzheimer’s disease (short-term treatment up to 6 weeks in a situation of consistent aggression), in patients who are not responding to non-pharmacological treatment and there is concern that they will harm themselves or others. – For treatment of mania in bipolar disorder. – For the treatment of behavioral disorders such as violence, impulsiveness and self aggression in children over 5 years of age and in adults who are intellectually handicapped.

    Read More

  • rispond 2

    RISPOND 2 – Risperidone

    For the treatment of schizophrenia and symptoms
    of psychotic disorders.
    – For long-term treatment in order to sustain the
    improvement in the state of the illness in patients
    who have exhibited an initial response.
    – For the treatment of psychotic manifestations of
    moderate to severe dementia, only in Alzheimer’s
    disease (short-term treatment up to 6 weeks in
    a situation of consistent aggression), in patients
    who are not responding to non-pharmacological
    treatment and there is concern that they will harm
    themselves or others.
    – For treatment of mania in bipolar disorder.
    – For the treatment of behavioral disorders such
    as violence, impulsiveness and self aggression in
    children over 5 years of age and in adults who are
    intellectually handicapped.


    RISPOND 2 – Risperidone

    For the treatment of schizophrenia and symptoms of psychotic disorders. – For long-term treatment in order to sustain the improvement in the state of the illness in patients who have exhibited an initial response. – For the treatment of psychotic manifestations of moderate to severe dementia, only in Alzheimer’s disease (short-term treatment up to 6 weeks in a situation of consistent aggression), in patients who are not responding to non-pharmacological treatment and there is concern that they will harm themselves or others. – For treatment of mania in bipolar disorder. – For the treatment of behavioral disorders such as violence, impulsiveness and self aggression in children over 5 years of age and in adults who are intellectually handicapped.

    Read More

  • rispond 3

    RISPOND 3 – Risperidone

    For the treatment of schizophrenia and symptoms
    of psychotic disorders.
    – For long-term treatment in order to sustain the
    improvement in the state of the illness in patients
    who have exhibited an initial response.
    – For the treatment of psychotic manifestations of
    moderate to severe dementia, only in Alzheimer’s
    disease (short-term treatment up to 6 weeks in
    a situation of consistent aggression), in patients
    who are not responding to non-pharmacological
    treatment and there is concern that they will harm
    themselves or others.
    – For treatment of mania in bipolar disorder.
    – For the treatment of behavioral disorders such
    as violence, impulsiveness and self aggression in
    children over 5 years of age and in adults who are
    intellectually handicapped.


    RISPOND 3 – Risperidone

    For the treatment of schizophrenia and symptoms of psychotic disorders. – For long-term treatment in order to sustain the improvement in the state of the illness in patients who have exhibited an initial response. – For the treatment of psychotic manifestations of moderate to severe dementia, only in Alzheimer’s disease (short-term treatment up to 6 weeks in a situation of consistent aggression), in patients who are not responding to non-pharmacological treatment and there is concern that they will harm themselves or others. – For treatment of mania in bipolar disorder. – For the treatment of behavioral disorders such as violence, impulsiveness and self aggression in children over 5 years of age and in adults who are intellectually handicapped.

    Read More

  • rispond-4-eng

    RISPOND 4 – Risperidone

    For the treatment of schizophrenia and symptoms
    of psychotic disorders.
    – For long-term treatment in order to sustain the
    improvement in the state of the illness in patients
    who have exhibited an initial response.
    – For the treatment of psychotic manifestations of
    moderate to severe dementia, only in Alzheimer’s
    disease (short-term treatment up to 6 weeks in
    a situation of consistent aggression), in patients
    who are not responding to non-pharmacological
    treatment and there is concern that they will harm
    themselves or others.
    – For treatment of mania in bipolar disorder.
    – For the treatment of behavioral disorders such
    as violence, impulsiveness and self aggression in
    children over 5 years of age and in adults who are
    intellectually handicapped.


    RISPOND 4 – Risperidone

    For the treatment of schizophrenia and symptoms of psychotic disorders. – For long-term treatment in order to sustain the improvement in the state of the illness in patients who have exhibited an initial response. – For the treatment of psychotic manifestations of moderate to severe dementia, only in Alzheimer’s disease (short-term treatment up to 6 weeks in a situation of consistent aggression), in patients who are not responding to non-pharmacological treatment and there is concern that they will harm themselves or others. – For treatment of mania in bipolar disorder. – For the treatment of behavioral disorders such as violence, impulsiveness and self aggression in children over 5 years of age and in adults who are intellectually handicapped.

    Read More

  • rispond solution

    RISPOND ORAL SOLUTION

    For the treatment of schizophrenia and symptoms
    of psychotic disorders.
    – For long-term treatment in order to sustain the
    improvement in the state of the illness in patients
    who have exhibited an initial response.
    – For the treatment of psychotic manifestations of
    moderate to severe dementia, only in Alzheimer’s
    disease (short-term treatment up to 6 weeks in
    a situation of consistent aggression), in patients
    who are not responding to non-pharmacological
    treatment and there is concern that they will harm
    themselves or others.
    – For treatment of mania in bipolar disorder.
    – For the treatment of behavioral disorders such
    as violence, impulsiveness and self aggression in
    children over 5 years of age and in adults who are
    intellectually handicapped.


    RISPOND ORAL SOLUTION

    For the treatment of schizophrenia and symptoms of psychotic disorders. – For long-term treatment in order to sustain the improvement in the state of the illness in patients who have exhibited an initial response. – For the treatment of psychotic manifestations of moderate to severe dementia, only in Alzheimer’s disease (short-term treatment up to 6 weeks in a situation of consistent aggression), in patients who are not responding to non-pharmacological treatment and there is concern that they will harm themselves or others. – For treatment of mania in bipolar disorder. – For the treatment of behavioral disorders such as violence, impulsiveness and self aggression in children over 5 years of age and in adults who are intellectually handicapped.

    Read More